VECT News and Press, VectivBio Holding AG From 05/19/22

Gainers: Palo Alto Networks (PANW) +11%. Bioceres Crop Solutions  (BIOX) +7%. VectivBio Holding AG (VECT) +7%. Aveanna Healthcare Holdings (AVAH) +6%. Fate Therapeutics (FATE) +5%. Losers: Foghorn Therapeutics  (FHTX) -26%. Ross Stores (ROST) -23%. Atara Biotherapeutics (A...

BASEL, Switzerland, May 09, 2022 (GLOBE NEWSWIRE) -- VectivBio Holding AG (“VectivBio”) (Nasdaq: VECT), a clinical-stage biopharmaceutical company pioneering novel transformational treatments for severe rare conditions, today announced that Luca Santarelli, M.D., Ph.D., Founde...

BASEL, Switzerland, April 21, 2022 (GLOBE NEWSWIRE) -- VectivBio Holding AG (“VectivBio”) (Nasdaq: VECT), a clinical-stage biopharmaceutical company pioneering novel transformational treatments for severe rare conditions, today announced the appointment of Patrick Malloy as Se...

VectivBio Holding AG (VECT) Q4 2021 Earnings Conference Call April 7, 2022 08:00 AM ET Company Participants Luca Santarelli - Founder and CEO and Board Member Claudia D’Augusta - Chief Financial Officer Christian Meyer - Chief Operating Officer Omar Khwaja - Chief Medical Officer Kevin...

The following slide deck was published by VectivBio Holding AG in conjunction with their 2022 Q4 earnings call. For further details see: VectivBio Holding AG 2022 Q4 - Results - Earnings Call Presentation

VectivBio press release (NASDAQ:VECT): FY GAAP EPS of -$3.23 misses by $0.27. Cash and cash equivalents were $102.7 million as of December 31, 2021, compared to $40.2 million during the same period in 2020. For further details see: VectivBio GAAP EPS of -$3.23 misses by $0.27

Significant Progress Across Multiple Programs with Key Upcoming Catalysts Beginning H2 2022 STARS Phase 3 Program of Apraglutide in Short Bowel Syndrome with Intestinal Failure (SBS-IF) On-Track for Topline Results at End of 2023 Cash Runway Extends Beyond Anticipated Re...

VectivBio (NASDAQ:VECT -1.0%) has signed a license agreement with Asahi Kasei Pharma for several indications for the next-generation GLP-2 analog candidate apraglutide. The indications include short bowel syndrome with intestinal failure (SBS-IF) and steroid-refractory acute graft-versus...

Exclusive License with Asahi Kasei Pharma to develop and commercialize Apraglutide in Japan includes $30 million upfront cash payment, eligibility for up to $170 million in development and commercial milestones and double-digit royalties on apraglutide sales in Japan Loan facili...

-- Apraglutide well-tolerated and does not require dose-adjustment in patients with severe renal disease -- -- Results demonstrate potential to reach 28% of SBS-IF patients with renal dysfunction who are underserved by currently available therapies -- BASEL, Switzerland, M...